Pharmaceuticals 2010, 3(7), 2322-2332; doi:10.3390/ph3072322
Artesunate: The Best Drug in the Treatment of Severe and Complicated Malaria
Department of Drug Discovery, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500, USA
*
Author to whom correspondence should be addressed.
Received: 28 June 2010 / Revised: 14 July 2010 / Accepted: 20 July 2010 / Published: 21 July 2010
(This article belongs to the Special Issue New Antimalarial Drugs)
View Full-Text
|
Download PDF [69 KB, uploaded 21 July 2010]
Abstract
This review summarizes progress in treating severe and complicated malaria, which are global problems, claiming at least one million lives annually, and have been accompanied by advances in our understanding of the pathogenesis of severe malaria complications. New drugs such as intravenous artesunate (AS) and intramuscular artemether (AM) are improving outcomes and decreasing malaria deaths. Trials comparing AM to the traditional parenteral drug, quinine, have not demonstrated however convincing evidence of a mortality advantage for AM. The South East Asian Quinine Artesunate Malaria Trials (SEAQUAMAT), a multicenter, randomized, open-label study comparing AS with quinine showed that parenteral AS was shown to be associated with a 35% reduction in the risk of mortality compare to quinine, and is now the recommended treatment by the WHO for severe and complicated malaria in low-transmission areas and in the second and third trimesters of pregnancy, with almost all the benefit reported in those with high parasite counts. Artesunate is a semisynthetic derivative of artemisinin whose water solubility facilitates absorption and provides an advantage over other artemisinins because it can be formulated as oral, rectal, intramuscular, and intravenous preparations. Artesunate is rapidly hydrolyzed to dihydroartemisinin, which is the most active schizonticidal metabolite. Injectable AS results in a more rapid systemic availability of AS compared with intramuscular AM. This pharmacokinetic advantage may provide a clinical advantage in the treatments of severe and complicated malaria. View Full-TextKeywords:
artesunate; artemether; quinine; quinidine; severe malaria; complicated malaria
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Scifeed alert for new publications
Never miss any articles matching your research from any publisher- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Share & Cite This Article
MDPI and ACS Style
Li, Q.; Weina, P. Artesunate: The Best Drug in the Treatment of Severe and Complicated Malaria. Pharmaceuticals 2010, 3, 2322-2332.
Related Articles
Article Metrics
Comments
[Return to top]
Pharmaceuticals
EISSN 1424-8247
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert